BiotechTV

BiotechTV - News

Science EN ↓ 484 avsnitt

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Glöm inte att besöka poddens webbplats och stötta skaparen: podcasters.spotify.com

Skapare

BiotechTV

Kategori

Science

Poddens webbplats

podcasters.spotify.com

Senaste avsnittet

2 okt 2026

Var kan du lyssna?

Poddar i appen Replaio Radio Kommer snart

Poddar kommer snart till appen. Installera nu och bli först med att uppleva ett helt nytt sätt att lyssna på poddar

Installera gratis Android nästan 10 mn nedladdningar · betyg 4,8 iOS snart

Avsnitt

Jefferies London: Jefferies Global Chairman of Healthcare Philip Ross discusses the environment for biotech and deals 18.11.2025 8:01

He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such as bi-specifics and tri-specifics.

Jefferies London: Chief Scientific Officer Tony Wood covers the latest highlights in GSK's pipeline, including oncology, respiratory, and inflammation 18.11.2025 11:35

He mentions momelotinib, Blenrep, B7-H3, depemokimab, efimosfermin, IL-33, TSLP, and more. Plus, GSK's dealmaking strategy.

Jefferies London: Zymeworks had double-news during London Life Science Week - a P3 success for its HER2 bispecific in gastroesophageal cancer and it also launched a new royalty model 18.11.2025 10:41

CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data.

Jefferies London: Protagonist Therapeutics CEO Dinesh Patel responds to takeout speculation and discusses the company's programs and culture of partnering 18.11.2025 10:06

He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program.

Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Olyer walks us through that and the whole pipeline 17.11.2025 10:09

He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners.

Jefferies London: Sofinnova Partners announced a new $750M fund XI today that will invest in early stage companies in biotech 17.11.2025 10:26

Chairman and managing partner Antoine Papiernik tells us about the fund and how he expects to deploy it. Plus, the current state of European biotech.

Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech 17.11.2025 4:41

He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific.

Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia 13.11.2025 4:12

He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP. 12.11.2025 12:26

CEO Michael Henderson walks us through what will be a busy year for the company.

Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year 12.11.2025 5:11

CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.

Stifel's Head of Global Equity Capital Markets Seth Rubin describes the investor feedback he is hearing about the sector lately and the fundraising environment for companies 12.11.2025 5:58

He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026.

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all 12.11.2025 8:36

CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans.

Stifel's I&I expert Alex Thompson shares his take on the environment and discusses names he covers that have key catalyst events 12.11.2025 12:21

He comments on Kymera, Apogee, Avalo, Veridian, Moonlake, Spyre, and Oruka.

Celcuity release what it believes is practice changing breast cancer data with its multi-target PAM inhibitor. Co-Founder & CEO Brian Sullivan describes why he believes the data is so important 11.11.2025 9:22

He discusses the pathway and gedatolisib's ability to cover it holistically. Plus, future plans for filing and additional data in breast cancer and beyond.

Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination that current therapies for IBD and rheumatology 11.11.2025 6:31

CEO Cameron Turtle describes the improvements Spyre is making in its therapies. 2026 is going to be a data rich year for IBD.

Vicore Pharma is leveraging in understanding the Renin-Angiotensin System (RAS) to develop angiotensin II type 2 receptor agonists for IPF and beyond 11.11.2025 6:49

CEO Ahmed Mousa walks us through the sciences and describes how data stacked up against a synthetic external control that was presented at a medical meeting this summer.

The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD 11.11.2025 9:37

CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs.

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss 11.11.2025 8:46

Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis.

Stifel's Head of Therapeutics Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events 11.11.2025 13:15

He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne.

Upstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile. 11.11.2025 7:47

CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile.

Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins 10.11.2025 10:31

Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human biochemistry, and the clinical benefits that could flow from that.

Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung 08.11.2025 9:41

CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.

Enara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1 08.11.2025 8:34

CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs 08.11.2025 11:53

The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.

Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC 08.11.2025 12:56

Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study.